Biopharmaceutical company – Discovery Development – Bispecific antibody – BiXAb Platform – Immunotherapeutics

BIOMUNEX is a biopharmaceutical company providing cutting-edge immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, created from its next-generation unique bispecific antibody proprietary BiXAb platform.
This modular technology enables the turnkey formatting of a BiXAb from any pair of monospecific mAbs as building blocks, in a timely and cost-effective manner. BiXAb enables BIOMUNEX to discover and develop drug candidates with high anti-tumor activity and true synergistic activity on its targets. Its pipeline will soon enable BIOMUNEX to become a clinical stage company.
In January 2019, Biomunex announced that it signed a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies.